Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 4/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.35 |
| ▸ | LMNA | P02545 | 3/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | GAA | P10253 | 3/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | GLA | P06280 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4876361 | 0.82 | KDM4E (0.38) | NPSR1KDM4ELMNAALDH1A1GAA | |
| SCHEMBL6909692 | 0.75 | KDM4E (0.40) | NPSR1KDM4ELMNAALDH1A1GAA | |
| SCHEMBL614374 | 0.59 | — | — | |
| SCHEMBL7128136 | 0.57 | ALDH1A1 (0.42) | KDM4EALDH1A1TDP1 | |
| SCHEMBL4877091 | 0.56 | HTR1A (0.35) | TDP1 | |
| SCHEMBL18792381 | 0.56 | LDHA (0.47) | KDM4EALDH1A1MAPT | |
| SCHEMBL4878997 | 0.56 | HTR1A (0.34) | MAPT | |
| SCHEMBL7127123 | 0.56 | SIRT3 (0.32) | KDM4ELMNAALDH1A1 | |
| SCHEMBL7130709 | 0.56 | L3MBTL1 (0.41) | NPSR1KDM4EALDH1A1MAPTL3MBTL1 | |
| SCHEMBL7939819 | 0.54 | HRH4 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040248883-A1 | Novel heteroaryl derivatives, their preparation and use | H. LUNDBECK A/S (DK) | 2004-12-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040248883-A1 | Novel heteroaryl derivatives, their preparation and use | GRIN2C, GRIN2B, HTR1A | NPSR1 67/4885KDM4E 3350/4885LMNA 3553/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.